Year archive

Calliditas Therapeutics — 2021 filings

All 51 regulatory filings released by Calliditas Therapeutics (CALTX) in 2021, sourced directly from the official regulator.

51 Filings

2021 Period

2021 filings (51)

Filing	Released	Lang
FDA beviljar Calliditas accelererat godkännande för behandling av patienter med primär IgA-nefrit med risk för snabb sjukdomsprogression Earnings Release FY 2021	2021-12-15	Swedish
Interim / Quarterly Report 2021 Interim / Quarterly Report 9M 2021	2021-11-18	Swedish
Interim / Quarterly Report 2021 Interim / Quarterly Report 9M 2021	2021-11-18	English
Major Shareholding Notification 2021 Major Shareholding Notification	2021-11-16	English
Calliditas Therapeutics’ nomination committee for the AGM 2022 Board/Management Information	2021-11-02	English
Calliditas Therapeutics valberedning utsedd inför årsstämma 2022 Board/Management Information	2021-11-02	Swedish
Updated regulatory timeline for review of MAA in Europe. Regulatory Filings	2021-09-16	English
Uppdaterad regulatorisk tidslinje för granskning av MAA i Europa Regulatory Filings	2021-09-16	Swedish
Förlängt PDUFA måldatum för Nefecon i USA Legal Proceedings Report	2021-09-14	Swedish
PDUFA goal date extension for Nefecon NDA in the U.S. Regulatory Filings	2021-09-14	English
Number of shares and votes in Calliditas Therapeutics Declaration of Voting Results & Voting Rights Announcements	2021-08-31	English
Antal aktier och röster i Calliditas Therapeutics Declaration of Voting Results & Voting Rights Announcements	2021-08-31	Swedish
Declaration of Voting Results & Voting Rights Announcements 2021 Declaration of Voting Results & Voting Rights Announcements	2021-08-26	English
Interim / Quarterly Report 2021 Interim / Quarterly Report H1 2021	2021-08-19	Swedish
Interim / Quarterly Report 2021 Interim / Quarterly Report H1 2021	2021-08-19	English
Major Shareholding Notification 2021 Major Shareholding Notification	2021-08-16	English
Calliditas Therapeutics has resolved on a directed share issue in the amount of 2.4 million shares, raising proceeds of approximately SEK 324 million Capital/Financing Update	2021-08-12	English
Calliditas Therapeutics har beslutat om en riktad nyemission om 2,4 miljoner aktier och tillförs härigenom cirka 324 miljoner kronor. Share Issue/Capital Change	2021-08-12	Swedish
Calliditas Therapeutics avser att genomföra en riktad nyemission Share Issue/Capital Change	2021-08-12	Swedish
Calliditas Therapeutics intends to carry out a directed share issue Capital/Financing Update	2021-08-12	English
Calliditas Therapeutics och STADA ingår avtal för att registrera och kommersialisera specialistläkemedel i Europa för IgA-nefropati Regulatory Filings	2021-07-21	Swedish
Calliditas Therapeutics and STADA partner to register and commercialize specialty therapy for IgA Nephropathy in Europe Regulatory Filings	2021-07-21	English
Calliditas ingår avtal om lånefacilitet på 75 miljoner dollar Capital/Financing Update	2021-07-16	Swedish
Calliditas secures $75 million term loan facility Capital/Financing Update	2021-07-16	English
Calliditas Announces Submission of Marketing Authorisation Application for Nefecon to the European Medicines Agency Regulatory Filings	2021-05-28	English
Calliditas har lämnat in ansökan om marknadsgodkännande (Marketing Authorisation Application) för Nefecon till EMA Regulatory Filings	2021-05-28	Swedish
Kommuniké från årsstämman i Calliditas Therapeutics AB (publ) AGM Information	2021-05-27	Swedish
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) AGM Information	2021-05-27	English
Interim / Quarterly Report 2021 Interim / Quarterly Report Q1 2021	2021-05-18	Swedish
Interim / Quarterly Report 2021 Interim / Quarterly Report Q1 2021	2021-05-18	English
FDA grants priority review for Nefecon, for patients with IgA nephropathy Regulatory Filings	2021-04-28	English
FDA beviljar prioriterad granskning av Nefecon för patienter med IgA-nefropati Earnings Release FY 2021	2021-04-28	Swedish
Annual Report 2020 Annual Report FY 2020	2021-04-27	Swedish
Annual Report 2020 Annual Report FY 2020	2021-04-27	English
Notice of annual general meeting of Calliditas Therapeutics AB (publ) AGM Information	2021-04-26	English
Kallelse till årsstämma i Calliditas Therapeutics AB (publ) AGM Information	2021-04-26	Swedish
EMA Grants Accelerated Assessment Procedure for Nefecon for the Treatment of IgA Nephropathy Legal Proceedings Report	2021-04-23	English
EMA beviljar accelererat bedömningsförfarande (Accelerated Assessment) för Nefecon för behandling av IgA-nefropati Regulatory Filings	2021-04-23	Swedish
Calliditas lämnar in ansökan till FDA för behandling med Nefecon för patienter med primär IgA-nefropati Regulatory Filings	2021-03-15	Swedish
Calliditas Announces Submission of New Drug Application to U.S. FDA for Nefecon in Patients with Primary IgA Nephropathy Earnings Release FY 2021	2021-03-15	English
Major Shareholding Notification 2021 Major Shareholding Notification	2021-03-08	English
Earnings Release 2020 Earnings Release FY 2020	2021-02-18	Swedish
Interim / Quarterly Report 2020 Interim / Quarterly Report FY 2020	2021-02-18	English
Declaration of Voting Results & Voting Rights Announcements 2021 Declaration of Voting Results & Voting Rights Announcements	2021-02-04	English
Major Shareholding Notification 2021 Major Shareholding Notification	2021-02-03	English
Calliditas meddelar att den föreslagna globala kapitalanskaffningen avbryts Capital/Financing Update	2021-01-28	Swedish
Calliditas announces termination of the proposed global offering Capital/Financing Update	2021-01-28	English
Calliditas Therapeutics launches proposed global offering Share Issue/Capital Change	2021-01-26	English
Calliditas Therapeutics offentliggör avsikt att genomföra en global kapitalanskaffning Share Issue/Capital Change	2021-01-26	Swedish
Calliditas announces clinical development plan for setanaxib and comments on data from Part A of NefIgArd study at today´s R&D Day Earnings Release FY 2021	2021-01-20	English
Calliditas offentliggör klinisk utvecklingsplan för setanaxib och presenterar data från del A i NefIgArd-studien vid dagens kapitalmarknadsdag Regulatory Filings	2021-01-20	Swedish